5/10/2013

Techulon landed a Phase II, $1.9 million contract with the U.S. Defense Advanced Research Projects Agency to further develop its therapeutic program for multidrug-resistant bacteria, or superbugs. The firm plans to use the money to take a nanotherapeutic agent toward clinical trials.

Related Summaries